HLB Innovation's Verismo to Unveil Preclinical Results for Solid Tumor CAR-T
Verismo Therapeutics, a U.S. subsidiary of HLB Innovation, will present preclinical results for its solid tumor CAR-T therapy at the Society for Immunotherapy of Cancer (SITC 2026) on November 6 (local time).
According to Verismo on October 16, the study compared the company’s multichain KIR-CAR T with single-chain CAR-T therapies based on CD28 or 4-1BB, which are commonly used in conventional CAR-T treatments, in vivo in preclinical models.
Unlike conventional CAR-T therapies, Verismo’s KIR-CAR uses a multichain structure that mimics the natural receptor structure of immune cells. While conventional CAR-T therapies combine the components needed for antigen recognition and T-cell activation into a single chain, KIR-CAR uses the KIR structure of natural killer (NK) cells, separating the antigen-binding and signaling components. The two components are designed to remain separate under normal conditions and bind to each other when they recognize a target antigen on a cancer cell, thereby triggering T-cell activation signals.
The mesothelin-targeting KIR-CAR used in this study is based on the technology used in SynKIR-110, which is currently undergoing a Phase 1 clinical trial in the United States. The preclinical results support the clinical development of SynKIR-110, which is being developed for patients with advanced solid tumors that express mesothelin, including ovarian cancer, cholangiocarcinoma and mesothelioma.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Brian Kim, CEO and co-founder of Verismo Therapeutics, said, "This study is significant because a direct comparison with conventional CAR-T therapies confirmed in vivo that the multichain KIR-CAR has distinct advantages in reducing T-cell exhaustion and cytokine release. We will continue developing SynKIR-110, which is currently in a Phase 1 clinical trial, and open up new possibilities for CAR-T treatment of solid tumors."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.